Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.

Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2016;51(4):1085-97. doi: 10.3233/JAD-150937.

PMID:
26967213
2.

Lack of neural compensatory mechanisms of BDNF val66met met carriers and APOE E4 carriers in healthy aging, mild cognitive impairment, and Alzheimer's disease.

Gomar JJ, Conejero-Goldberg C, Huey ED, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Mar;39:165-73. doi: 10.1016/j.neurobiolaging.2015.12.004. Epub 2015 Dec 19.

PMID:
26923413
3.

A Multisite, Randomized Controlled Clinical Trial of Computerized Cognitive Remediation Therapy for Schizophrenia.

Gomar JJ, Valls E, Radua J, Mareca C, Tristany J, del Olmo F, Rebolleda-Gil C, Jañez-Álvarez M, de Álvaro FJ, Ovejero MR, Llorente A, Teixidó C, Donaire AM, García-Laredo E, Lazcanoiturburu A, Granell L, Mozo Cde P, Pérez-Hernández M, Moreno-Alcázar A, Pomarol-Clotet E, McKenna PJ; Cognitive Rehabilitation Study Group.

Schizophr Bull. 2015 Nov;41(6):1387-96. doi: 10.1093/schbul/sbv059. Epub 2015 May 25.

4.

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder.

Amann BL, Canales-Rodríguez EJ, Madre M, Radua J, Monte G, Alonso-Lana S, Landin-Romero R, Moreno-Alcázar A, Bonnin CM, Sarró S, Ortiz-Gil J, Gomar JJ, Moro N, Fernandez-Corcuera P, Goikolea JM, Blanch J, Salvador R, Vieta E, McKenna PJ, Pomarol-Clotet E.

Acta Psychiatr Scand. 2016 Jan;133(1):23-33. doi: 10.1111/acps.12440. Epub 2015 May 13.

PMID:
25968549
5.

Predictive factors of functional capacity and real-world functioning in patients with schizophrenia.

Menendez-Miranda I, Garcia-Portilla MP, Garcia-Alvarez L, Arrojo M, Sanchez P, Sarramea F, Gomar J, Bobes-Bascaran MT, Sierra P, Saiz PA, Bobes J.

Eur Psychiatry. 2015 Jul;30(5):622-7. doi: 10.1016/j.eurpsy.2014.12.011. Epub 2015 Feb 10.

PMID:
25681175
6.

Reply to: the impact of magnetic resonance spectroscopy in elucidating the role of apolipoprotein E ε4 in preclinical Alzheimer's disease.

Gomar JJ, Kingsley PB, Uluğ AM, Conejero-Goldberg C, Barker P, Goldberg TE.

Biol Psychiatry. 2015 Apr 15;77(8):e41-2. doi: 10.1016/j.biopsych.2014.06.028. Epub 2014 Jul 21. No abstract available.

PMID:
25152433
7.

[Development of the Spanish brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder].

Garcia-Portilla MP, Gomar J, Bobes-Bascaran MT, Menendez-Miranda I, Saiz PA, Muñiz J, Arango C, Patterson T, Harvey P, Bobes J, Goldberg T.

Rev Psiquiatr Salud Ment. 2014 Jul-Sep;7(3):113-20. doi: 10.1016/j.rpsm.2014.02.003. Epub 2014 Jun 29. Spanish.

8.

Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data.

Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Nov;10(6):704-12. doi: 10.1016/j.jalz.2013.11.009. Epub 2014 Mar 6.

9.

APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms.

Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, Hyde TM, Kleinman JE, Herman MM, Chen S, Davies P, Goldberg TE.

Mol Psychiatry. 2014 Nov;19(11):1243-50. doi: 10.1038/mp.2013.194. Epub 2014 Feb 4.

PMID:
24492349
10.

Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder.

Garcia-Portilla MP, Gomar JJ, Bobes-Bascaran MT, Menendez-Miranda I, Saiz PA, Muñiz J, Arango C, Patterson TL, Harvey PD, Bobes J, Goldberg TE.

Schizophr Res. 2013 Nov;150(2-3):421-6. doi: 10.1016/j.schres.2013.07.049. Epub 2013 Sep 19.

PMID:
24055246
11.

APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain.

Gomar JJ, Gordon ML, Dickinson D, Kingsley PB, Uluğ AM, Keehlisen L, Huet S, Buthorn JJ, Koppel J, Christen E, Conejero-Goldberg C, Davies P, Goldberg TE.

Biol Psychiatry. 2014 May 1;75(9):686-92. doi: 10.1016/j.biopsych.2013.05.022. Epub 2013 Jul 5.

12.

Comment on "Cognition in schizophrenia: Summary Nice Consultation Meeting 2012".

Goldberg TE, Gomar JJ.

Eur Neuropsychopharmacol. 2013 Aug;23(8):788-9. doi: 10.1016/j.euroneuro.2013.04.009. Epub 2013 May 22. No abstract available.

PMID:
23706575
13.

Structural brain changes associated with tardive dyskinesia in schizophrenia.

Sarró S, Pomarol-Clotet E, Canales-Rodríguez EJ, Salvador R, Gomar JJ, Ortiz-Gil J, Landín-Romero R, Vila-Rodríguez F, Blanch J, McKenna PJ.

Br J Psychiatry. 2013 Jul;203(1):51-7. doi: 10.1192/bjp.bp.112.114538. Epub 2012 Dec 6.

14.

Semantic distance abnormalities in mild cognitive impairment: their nature and relationship to function.

Kirchberg BC, Cohen JR, Adelsky MB, Buthorn JJ, Gomar JJ, Gordon M, Koppel J, Christen E, Conejero-Goldberg C, Davies P, Goldberg TE.

Am J Psychiatry. 2012 Dec;169(12):1275-83.

PMID:
23139013
15.

Effect of the interleukin-1β gene on dorsolateral prefrontal cortex function in schizophrenia: a genetic neuroimaging study.

Fatjó-Vilas M, Pomarol-Clotet E, Salvador R, Monté GC, Gomar JJ, Sarró S, Ortiz-Gil J, Aguirre C, Landín-Romero R, Guerrero-Pedraza A, Papiol S, Blanch J, McKenna PJ, Fañanás L.

Biol Psychiatry. 2012 Nov 1;72(9):758-65. doi: 10.1016/j.biopsych.2012.04.035. Epub 2012 Jul 3.

PMID:
22763186
16.

Executive dysfunction and memory impairment in schizoaffective disorder: a comparison with bipolar disorder, schizophrenia and healthy controls.

Amann B, Gomar JJ, Ortiz-Gil J, McKenna P, Sans-Sansa B, Sarró S, Moro N, Madre M, Landin-Romero R, Vieta E, Goikolea JM, Salvador R, Pomarol-Clotet E.

Psychol Med. 2012 Oct;42(10):2127-35. doi: 10.1017/S0033291712000104. Epub 2012 Feb 23. Erratum in: Psychol Med. 2012 Oct;42(10):2136. Giokolea, J M [corrected to Goikolea, J M].

PMID:
22357405
17.

Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume.

Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2012 Jun;33(6):1124.e31-41. doi: 10.1016/j.neurobiolaging.2011.08.016. Epub 2011 Dec 14.

18.

Development and cross-validation of the UPSA short form for the performance-based functional assessment of patients with mild cognitive impairment and Alzheimer disease.

Gomar JJ, Harvey PD, Bobes-Bascaran MT, Davies P, Goldberg TE.

Am J Geriatr Psychiatry. 2011 Nov;19(11):915-22. doi: 10.1097/JGP.0b013e3182011846.

PMID:
22024615
19.

Awareness of cognitive impairment in schizophrenia and its relationship to insight into illness.

González-Suárez B, Gomar JJ, Pousa E, Ortiz-Gil J, García A, Salvador R, Sans-Sansa B, Pomarol-Clotet E, McKenna PJ.

Schizophr Res. 2011 Dec;133(1-3):187-92. doi: 10.1016/j.schres.2011.08.023. Epub 2011 Sep 23.

PMID:
21945548
20.

Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.

Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Arch Gen Psychiatry. 2011 Sep;68(9):961-9. doi: 10.1001/archgenpsychiatry.2011.96.

PMID:
21893661
Items per page

Supplemental Content

Loading ...
Write to the Help Desk